| Intravascular ultrasound findings in ENDEAVOR II and ENDEAVOR III. | |
| | |
MedLine Citation:
|
PMID: 17950835 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The results of 2 randomized controlled trials of the Endeavor zotarolimus-eluting stent (ZES; Medtronic Vascular, Santa Rosa, CA) were recently reported: ENDEAVOR II, in which the Endeavor stent was compared with the Driver bare metal stent (BMS; Medtronic Vascular), and ENDEAVOR III, in which the Endeavor stent was compared with the first-generation Cypher sirolimus-eluting stent (SES; Cordis Corporation, Miami Lakes, FL). To examine in detail the vascular responses to the Endeavor stent, serial intravascular ultrasound (IVUS) analyses were performed in subsets of patients in the 2 trials at baseline and 8-month follow-up. The investigators report results for various IVUS parameters and compare those with published results for the first-generation SES and paclitaxel-eluting stent (PES). The ZES demonstrated significantly improved effectiveness and equivalent safety compared with the BMS in ENDEAVOR II. Although the ZES seems to be slightly less effective at inhibiting intimal hyperplasia than the SES and PES, early results are indicative of an acceptable safety profile. This finding may be due in part to the relatively complete and uniform neointimal coverage associated with the ZES. |
| | |
Authors:
|
Ryota Sakurai; Heidi N Bonneau; Yasuhiro Honda; Peter J Fitzgerald |
Related Documents
:
|
11696295 - Update on in-stent restenosis. 11153775 - Arterial remodeling influences the development of intimal hyperplasia after stent impla... 12622445 - Exacerbation of lambert-eaton myasthenic syndrome caused by an l-type ca2+ channel anta... 19543785 - Reduction of neointimal hyperplasia in porcine coronary arteries by 2-deoxy-d-glucose. 2185435 - Colour doppler imaging of arteriovenous malformation of the vein of galen in a newborn. 21654535 - History of the vertebral venous plexus and the significant contributions of breschet an... |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial |
Journal Detail:
|
Title: The American journal of cardiology Volume: 100 ISSN: 0002-9149 ISO Abbreviation: Am. J. Cardiol. Publication Date: 2007 Oct |
Date Detail:
|
Created Date: 2007-10-22 Completed Date: 2007-12-06 Revised Date: 2008-06-05 |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 71M-76M Citation Subset: AIM; IM |
Affiliation:
|
Center for Cardiovascular Technology, Stanford University Medical Center, Stanford, California 94305-5637, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Bacterial Agents
/
administration & dosage,
therapeutic use* Coronary Disease / drug therapy* Double-Blind Method Drug-Eluting Stents* Female Follow-Up Studies Humans Hyperplasia Male Middle Aged Sirolimus / administration & dosage, analogs & derivatives*, therapeutic use Tunica Intima / drug effects, pathology*, ultrasonography |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents; 0/zotarolimus; 53123-88-9/Sirolimus |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The relation between clinical features, angiographic findings, and the target lesion revascularizati...
Next Document: Real-world safety and efficacy of the endeavor zotarolimus-eluting stent: early data from the E-Five...